|
流感病毒传染性NIB-129[H3N2]22/118
|
EA
|
22/118
|
咨询
|
1-4/12周
|
|
第1批国际标准2023年裂谷热病毒抗体中和测定[人血浆]22/104_NT
|
EA
|
22/104_NT
|
4988
|
1-4/12周
|
|
SARS-Cov-2抗原第1批WHO国际标准21/368
|
EA
|
21/368
|
4988
|
1-4/12周
|
|
流感病毒传染性SAN-011[H1N1]21/366
|
EA
|
21/366
|
咨询
|
1-4/12周
|
|
流感病毒传染性X-367A[H3N2]21/382
|
EA
|
21/382
|
咨询
|
1-4/12周
|
|
流感病毒传染性X-369A[H3N2]21/384
|
EA
|
21/384
|
咨询
|
1-4/12周
|
|
WHO参考试剂抗人白细胞抗原抗体[弱阳性血浆]21/378
|
EA
|
21/378
|
4988
|
1-4/12周
|
|
流感病毒传染性IVR-208[H3N2]21/380
|
EA
|
21/380
|
咨询
|
1-4/12周
|
|
第1批抗拉沙热病毒抗体国际参考盘21/332
|
EA
|
21/332
|
10203
|
1-4/12周
|
|
卵泡刺激素和黄体生成素,人,尿[第6批WHO国际标准]21/344
|
EA
|
21/344
|
4988
|
1-4/12周
|
|
流感病毒传染性A/维多利亚/2570/2019[H1N1]21/346
|
EA
|
21/346
|
咨询
|
1-4/12周
|
|
WHO第2批抗SARS-CoV-2免疫球蛋白国际标准.21/340
|
EA
|
21/340
|
4988
|
1-4/12周
|
|
2022年第1批国际标准SARS-CoV-2相关变体抗体21/338
|
EA
|
21/338
|
4988
|
1-4/12周
|
|
流感病毒传染性B/华盛顿/02/2019[B-维多利亚谱系]21/336
|
EA
|
21/336
|
咨询
|
1-4/12周
|
|
B型流感抗原/奥地利/1359417/2021[BVR-26][B维多利亚谱系]21/316
|
EA
|
21/316
|
4081
|
1-4/12周
|
|
流感抗原A/达尔文/6/2021[IVR-227][H3N2]21/314
|
EA
|
21/314
|
4081
|
1-4/12周
|
|
流感抗原A/达尔文/9/2021[IVR-228][H3N2]21/318
|
EA
|
21/318
|
4081
|
1-4/12周
|
|
流感抗B型神经氨酸酶血清[B/普吉岛/3073/2013]21/322
|
EA
|
21/322
|
4081
|
1-4/12周
|
|
流感抗原B/密歇根/01/2021[B/维多利亚谱系]21/330
|
EA
|
21/330
|
4081
|
1-4/12周
|
|
流感抗原A/达尔文/9/2021[SAN-010][H3N2]21/320
|
EA
|
21/320
|
4081
|
1-4/12周
|
